NCT06699602View on ClinicalTrials.gov

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Cemiplimab

cemiplimab IV flat

DRUG

Fianlimab

fianilmab IV flat

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York

10604

RECRUITING

Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER